Andrew Bernhisel, Attilio Orazi, Sumit Guar, Vijay Tonk, Reshad Ghafouri Sayed, Osvaldo Padilla
Medical student, Paul Foster School of Medicine, Texas Tech Health Sciences Center at El Paso, TX.
Department of Pathology, Texas Tech Health Sciences Center at El Paso, TX.
Leuk Res Rep. 2021 Jun 1;15:100250. doi: 10.1016/j.lrr.2021.100250. eCollection 2021.
The inv(7)(p15q34) chromosomal abnormality which juxtaposes part of the HOXA gene cluster on 7p15 to the TCRβ locus on 7q34, has been described in a subset of cases of T-cell lymphoblastic leukemia, but its presence in cases of B-cell lymphoblastic leukemia is virtually unknown. Herewith, we report a case of a B-cell lymphoblastic leukemia with inv(7)(p15q34). The patient received standard induction chemotherapy, which failed to produce remission. After treatment with blinatumomab, a bispecific T-cell engager, the follow-up bone marrow biopsy showed no evidence of persistent/ relapsed B-cell lymphoblastic leukemia. The unique cytogenetics of this case may have contributed to its resistance of standard induction chemotherapy.
inv(7)(p15q34)染色体异常将7号染色体短臂15区的部分HOXA基因簇与7号染色体长臂34区的TCRβ基因座并列，已在一部分T细胞淋巴母细胞白血病病例中被描述，但在B细胞淋巴母细胞白血病病例中的存在情况几乎无人知晓。在此，我们报告一例伴有inv(7)(p15q34)的B细胞淋巴母细胞白血病病例。该患者接受了标准诱导化疗，但未达到缓解。在用双特异性T细胞衔接器blinatumomab治疗后，后续骨髓活检显示没有持续性/复发性B细胞淋巴母细胞白血病的证据。该病例独特的细胞遗传学特征可能导致了其对标准诱导化疗的耐药性。
